Notal Vision, Inc.

Based in the US, Notal Vision, Inc. is a diagnostic company focused on innovative digital health solutions for managing age-related macular degeneration (AMD) through advanced home monitoring technologies. Notal Vision, Inc. was founded in 2000 and is headquartered in Manassas, US.

The company specializes in the development of diagnostic technologies aimed at improving the management of AMD. The founders include Axelle Alibert and Barak Azmon, with Axelle Alibert currently serving as CEO. Notal Vision has completed 4 funding rounds, with the latest being a Series D round that raised USD 60. 00 mn from investors such as Elron Ventures, Evergreen Partners, Ganot, and Soleus Capital Management, bringing the total amount raised to USD 60.

00 mn and establishing a current company valuation of USD 274. 29 mn. Notal Vision specializes in innovative digital health solutions targeting the management of age-related macular degeneration (AMD) through home-based monitoring technologies. The company's core product, ForeseeHome®, serves as an early warning system, enabling physicians to diagnose wet AMD earlier and improve long-term visual outcomes for patients.

This system facilitates real-time patient monitoring and provides automated analysis of home-based optical coherence tomography (OCT) images through the proprietary Notal OCT Analyzer. Additionally, Notal Vision's diagnostic devices empower patients to conduct tests from home, thereby extending eye disease management beyond the traditional clinical setting and catering to both physicians and patients. The products primarily serve the U. S.

market, with potential applications in Europe and other regions where AMD prevalence necessitates improved monitoring and treatment strategies. Notal Vision generates revenue through direct transactions for its diagnostic products and services, primarily via subscription models that facilitate ongoing patient monitoring and data analysis. Physicians and healthcare practices implement the ForeseeHome® system to enhance patient care, ultimately leading to consistent revenue flow as they utilize the technology for managing AMD. The pricing structure for their offerings includes the provision of home-based diagnostic devices and continuous access to the AI-driven analysis platform, which streamlines the diagnostic process for eye care professionals.

By fostering partnerships with healthcare providers, Notal Vision ensures integration of its products into existing treatment paradigms, reinforcing its market position. The emphasis on precision medicine and patient-operated devices aligns with the growing demand for telehealth solutions in ophthalmic care. Notal Vision plans to leverage the recent funding round to enhance product development and expand its market reach. The company is working on upcoming innovations in its diagnostic product line, with specific release dates to be announced.

Additionally, Notal Vision aims to target expansion into European markets by 2025 and strengthen its presence in regions experiencing a rising prevalence of AMD. The funding will support these strategic initiatives, positioning Notal Vision for future growth in the digital health landscape.